CRH Medical Corp. | StockChase
81
CRH Medical Corp. (CRH-T)

Last Price Recorded: $2.5200 on 2017-11-24

ON STOCKCHASE SINCE Jul 2009

biotechnology/pharmaceutical

CRH Medical Corp.


Signal Opinion Expert
     

2016-06-30

BUY on WEAKNESS
CRH Medical Corp. (CRH-T)

This has had a move at around the $4.50 level followed by a breakout. A pretty volatile stock. It looks like it wants to come back, so if you don’t own it, you will probably get your chance. If it gets about $5.10, it looks like it wants to have the $7 target. The whole space is a good place to be.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $5.030
Owned: Unknown

2016-06-03

COMMENT
CRH Medical Corp. (CRH-T)

A little small for him, so he doesn’t own it. This is one of the healthcare rollup’s that has done it right. Valuation is pretty reasonable, especially one compared to some of their peers. They beat on their recent quarter, and are starting to generate cash flow. The balance sheet is in very good shape. They have managed to do acquisitions without debt, which is key for this type of business.

biotechnology/pharmaceutical
Jason Mann

CIO & Co-Founder, Edgehill Patners

Price: $4.360
Owned: No

2016-05-19

COMMENT
CRH Medical Corp. (CRH-T)

They are in the gastro anesthesiology business.  They have found a couple of pretty good niches.  They are market leaders in the markets they are operating in.  They are now integrating the acquisitions.  Impressive management team.  It is a growth stock and not a value stock.  He would like to meet them, however.

biotechnology/pharmaceutical
Lorne Steinberg

President & Portfolio Manager, Lorne Steinberg Wealth Management Inc

Price: $3.880
Owned: No

2016-05-12

PAST TOP PICK
CRH Medical Corp. (CRH-T)

(Top Pick Jun 19/15, Down 9.00%) They have done a good job.  They don’t need to raise prices.  9 times earnings.  They are probably looking for acquisitions.  The balance sheet looks good.  A premier small cap name so he continues to hold it.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $3.730
Owned: Yes

2016-04-21

WEAK BUY
CRH Medical Corp. (CRH-T)

A good health care services firm. This would be a Hold to a Weak Buy at this time. Really likes what they have done longer-term. If you can get this at the bottom of the 52 week trading range, that would be his Buy point. He likes management and what they are doing long term.

biotechnology/pharmaceutical
Alex Ruus

Portfolio Manager, Arrow Capital Management

Price: $4.000
Owned: Unknown

2016-04-07

DON'T BUY
CRH Medical Corp. (CRH-T)

From a seasonal perspective, you want to be looking more to the June timeframe. The chart shows a bit of resistance, and is now pulling back. There is a bit of head and shoulders topping pattern, which implies downside potential to almost $3.60. There is probably not much reason to get into this.

biotechnology/pharmaceutical
Jon Vialoux

Research Analyst, Timingthemarket.ca & Equityclock.com

Price: $4.240
Owned: Unknown

2016-04-06

COMMENT
CRH Medical Corp. (CRH-T)

He is generally negative on the rollup space, because it is a business that relies on having a high valuation in order to acquire other businesses. As soon as that game stops, the stocks can have a long way to fall before finding a bottom. This one is a little different in that they managed to not get caught up as much in the selloff. Because of that, it’s price momentum is quite good. Valuation is reasonable, which is unusual for a rollup. He doesn’t have a position in this, but it is on the cusp of being a Long for him.

biotechnology/pharmaceutical
Jason Mann

CIO & Co-Founder, Edgehill Patners

Price: $4.310
Owned: No

2016-03-16

BUY on WEAKNESS
CRH Medical Corp. (CRH-T)

It is in the right space.  Technically it has been a tough go for medical last year.  It is one of the few sectors that is in a secular bull market.  There is a downtrend that may have broken.  This would be one you could add to.  There will be some resistance until $5.10.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $4.440
Owned: Unknown

2016-03-07

STRONG BUY
CRH Medical Corp. (CRH-T)

Colonoscopy clinics. His 5th largest holding. Just delivered an excellent quarter. Very attractively priced, and run by a very honest management team. A very clean model of a health care stock. ROE is about 33% and P/E ratio is around 11%. Doesn’t believe there will be any equity financing, so no dilution going forward. Can’t think of a better company to own.

biotechnology/pharmaceutical
Jason Donville

President & CEO, Donville Kent Asset Management

Price: $4.360
Owned: Yes

2016-02-24

COMMENT
CRH Medical Corp. (CRH-T)

A great little company, and thinks they are going to continue to execute the way they have. Made a big transformational deal in 2014, and now are adding on small deals as they come across them. Doing this all with cash flow. You should continue to see earnings numbers increase as they make acquisitions. Has broken down on a technical aspect, but he is watching it closely, and at some time would like to add it to his portfolio.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $3.710
Owned: No

2016-02-19

HOLD
CRH Medical Corp. (CRH-T)

He is looking for support and resistance, and this is in the very tight channel. At $3.59, you are probably dealing with a $4.50 upside right now. The downside is quite good at around $2.80. It doesn’t look like a trade, but something that you would continue to Hold.

biotechnology/pharmaceutical
Elliot Fishman

Director, US & International Equity Trading Portfolio Adviso

Price: $3.590
Owned: Unknown

2016-02-08

BUY
CRH Medical Corp. (CRH-T)

They have gone through some lumps.  Analysts are expecting earnings growth of 69%.  It looks like they finally turned the company around.  14 times PE. 

biotechnology/pharmaceutical
Robert McWhirter

President, Selective Asset Management

Price: $3.460
Owned: Unknown

2016-01-13

COMMENT
CRH Medical Corp. (CRH-T)

Owned this in the past, and has his eye on it. The larger part of their business is providing anaesthesiology services to gastrointestinal doctors who are doing mostly colonoscopies. The majority of their business is done in the US. Attractive at these levels.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $3.540
Owned: No

2016-01-08

BUY
CRH Medical Corp. (CRH-T)

He likes this. It has been fairly strong over the last couple of weeks. Good management team. The cash flow from operations should rise quite a bit this year. Probably trading at around 8X 2016 EBITDA. If you are going to own something in this space, this is a go to name.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $3.940
Owned: Yes

2015-12-23

PAST TOP PICK
CRH Medical Corp. (CRH-T)

(A Top Pick Dec 24/14. Up 126.47%.) Still a Buy. ROE is over 30%. Trading at about 8.9X earnings and 2X Book. Funding all their growth through their own cash flows. Showing all the signs of becoming one of the great stocks.

biotechnology/pharmaceutical
Jason Donville

President & CEO, Donville Kent Asset Management

Price: $3.850
Owned: Yes

Showing 46 to 60 of 81 entries
<< < 2 3 4 5 6 > >>

No Comments.


You must be logged in to comment.